This clinical trial, sponsored by M.D. Anderson Cancer Center, aims to evaluate the efficacy of venetoclax in combination with a fractionated busulfan regimen for patients with high-risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The market for AML and MDS therapies is significant, with increasing demand for innovative treatments that improve patient outcomes. If successful, this trial could position venetoclax as a key component in the treatment of high-risk AML and MDS, potentially enhancing its market share against existing therapies. The trial's design includes both Phase II and Phase III components, indicating a robust approach to validating efficacy and safety, which may attract interest from investors and pharmaceutical partners. The competitive landscape includes other therapies targeting similar patient populations, necessitating a strong differentiation strategy based on clinical outcomes.